FAQ

Mitoxantrone

Known as: 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone, 1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione, Mitoxantronum 
An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-2018
010020019752018

Related topics

Related topics

50 relations

Narrower (23)

(mitoxantrone)cerium(IV)BBR 2577BBR3378CL 232315
(More)

Broader (4)

AnalgesicsAntineoplastic AgentsTopoisomerase II Inhibitorsanthracene
Drug AllergyEtoposide/Ifosfamide/Mesna/MitoxantroneIn BloodLeukemia, Myelocytic, Acute
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Mitoxantrone
Pain
Mammary Neoplasms
Drug Allergy
Prostatic Neoplasms
Pregnancy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK (J S de Bono FRCP); Tulane University, New… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
PURPOSE The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
BACKGROUND Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
BACKGROUND Treatment options for patients with secondary progressive multiple sclerosis are few. Encouraging results in open… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo.
Hematopoietic stem cells (HSCs) can be identified by a "side population" (SP) phenotype. Previous studies have implicated the ATP… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein or the multidrug-resistance… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
BACKGROUND Human cancer cell lines grown in the presence of the cytotoxic agent mitoxantrone frequently develop resistance… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
Mouse fibroblast cell lines lacking functional Mdr1a, Mdr1b, and Mrp1 genes were selected for resistance to topotecan… (More)
  • table 1
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
PURPOSE To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant… (More)
Is this relevant?